Vitamin K Cycle, Carboxylation, and Gla Proteins
Vitamin K (K1/phylloquinone: green vegetables; K2/menaquinone: MK-4 (tissue-synthesised from K1 via UBIAD1 geranylgeranyl transferase; brain/testis/pancreas); MK-7 (gut bacteria; Bacteroides/Fusobacterium/Peptostreptococcus; also B. subtilis in natto; long half-life ~70h vs K1 ~1h; superior carboxylation support); K3/menadione (synthetic; Mn2+-activated; hepatotoxic at high dose)): vitamin K cycle: KH2 (vitamin K hydroquinone; active donor form) + O2 → GGCX (gamma-glutamyl carboxylase; ER; multi-pass TM; requires KH2, CO2/HCO3, O2; carboxylates specific Glu residues (clusters of 2–12 within 12-residue Gla domain) to γ-carboxyglutamic acid (Gla; two carboxylate groups → Ca2+-chelation; conformational activation)); KH2 → KO (vitamin K epoxide; product of GGCX reaction); VKOR/VKORC1 (vitamin K epoxide reductase complex 1; ER; 4 TM; warfarin target; KO → K1 → K-reductase → KH2; warfarin blocks KO → K1 step → Gla proteins all ↓); VKORC1L1 (second isoform; warfarin-resistant; may maintain extrahepatic Gla protein carboxylation). Gla proteins (matrix/membrane-bound; Ca2+-dependent): coagulation (FII/VII/IX/X/PC/PS/PZ; liver; PIVKA (proteins induced by VK absence or antagonism) = uncarboxylated; measured by PIVKA-II in hepatocellular carcinoma); bone (osteocalcin/BGP; 3 Gla at Glu17/21/24; Ca2+/HAP binding; regulates osteoblast mineralisation; cOC (carboxylated) vs ucOC (uncarboxylated; insulin sensitiser; β-cell; adiponectin; muscle GLUT4)); vascular (MGP (matrix Gla protein; 5 Gla + 2 Ser phosphorylation; localised to vascular smooth muscle cell and cartilage matrix; carboxylated MGP (cMGP) binds BMP-2/4 → SMAD1/5/8 → RUNX2 ↓ → VSMCs calcification ↓; ucMGP (dp-ucMGP; dephosphorylated uncarboxylated) = inactive; accumulates in calcified plaques; dp-ucMGP serum biomarker of vascular K2 status; Gas6 (growth arrest-specific protein 6; Gla domain; AXL/Tyro3/Mer TAM receptors; apoptotic cell clearance/platelet activation)).
Spirulina Mechanisms in Vitamin K Carboxylation
Gut Microbiome MK-7 Menaquinone Production
Menaquinones (MK-n; n = prenyl chain length; MK-4 to MK-13; tissue-specific: MK-4 (brain, testis, pancreas; not gut-derived; requires UBIAD1 conversion from phylloquinone); MK-7/8/9/10/11 (gut-derived; synthesised by: Bacteroides fragilis (MK-10/11); Veillonella parvula (MK-7); Fusobacterium nucleatum (MK-7/8); Prevotella (MK-11/12)); MK-7 (USDA NDB: natto highest source; bone osteocalcin/MGP preferred over K1 for extrahepatic carboxylation; half-life ~68h; once-weekly dosing possible)): spirulina supports gut MK synthesis through prebiotic fibre (spirulina polysaccharides/β-glucan-like structures → Bacteroidetes/Prevotellaceae ↑ → MK-10/11 production → portal uptake → tissue distribution); additionally Nrf2 → UBIAD1 (geranylgeranyl transferase; converts K1 → MK-4 in non-gut tissues; Nrf2/ARE has UBIAD1 promoter ARE-like motif; +5–10% UBIAD1 in Nrf2-activated models) → MK-4 in brain/testis/pancreas; spirulina vitamin K1 content (~100–200 μg/100g; phylloquinone in chlorophyll-containing tissues; at 10g: 10–20 μg K1; ~10–15% adequate intake; modest but UBIAD1 substrate for MK-4 synthesis).
GGCX and Carboxylation Enzyme Support
GGCX (gamma-glutamyl carboxylase; GGCX gene; ER; single 758-aa protein; KH2-binding (BRS motif; residues 395–408); propeptide recognition (BRS; -20 to -10 of Gla domain protein; directs carboxylation processivity); Glu carboxylation: KH2 + O2 → KO + CO2 carbanion → Glu γ-CH → Gla (vitamin K-dependent carboxylation; electron abstraction mechanism); GGCX mutations: combined VKD clotting factor deficiency (VKCFD); KH2 stoichiometry: 1 KH2 consumed per Gla formed; for osteocalcin (3 Gla): 3 KH2; for MGP (5 Gla): 5 KH2): spirulina supports GGCX substrate supply: (1) vitamin K1 provision (10–20 μg/10g; GGCX KH2 substrate precursor); (2) VKORC1 enzyme support: Nrf2-driven antioxidant protection of VKORC1 Cys132/Cys135 active site thiol (VKORC1 uses a Cys-X-X-Cys motif for KO → K reduction; oxidative inactivation protected by Nrf2-GSH); (3) magnesium cofactor provision (GGCX requires Mg2+ for KH2/O2 binding; spirulina ~195 mg Mg/100g; at 10g: ~20 mg Mg; cofactor pool support); (4) ER protein homeostasis (Nrf2 → UPR attenuation → GGCX ER folding maintained; GGCX is ER-resident and dependent on proper ER environment).
Osteocalcin Gla Activation and Bone Mineral Density
Osteocalcin (OC/BGP; osteoblast-specific; 3 Gla residues (Glu17/21/24 → Gla17/21/24); cOC binds hydroxyapatite (HAP) Ca2+ → bone mineralisation regulation; ucOC (not carboxylated) is bioactive hormone: ucOC → GPRC6A (G protein-coupled receptor; osteocalcin receptor; pancreas, testis, muscle) → insulin secretion (β-cell) + GLUT4/testosterone production + muscle IL-6/AMPK; carboxylated osteocalcin ratio (cOC:ucOC) reflects vitamin K status; K2 deficiency → ucOC ↑ → bone mineralisation ↓ + ucOC hormonal effects ↑ (complex: some ucOC beneficial for metabolic function)): spirulina supports osteocalcin carboxylation: (1) vitamin K1 → MK-4 (UBIAD1; osteoblast-specific MK-4; K2 preferred for osteocalcin carboxylation in bone); (2) MGP carboxylation: spirulina K1 (10–20 μg/10g) + gut MK-7 production → bone osteocalcin cOC +5–10%; additionally: (3) K2-independent bone mechanisms: AMPK → Runx2 + Osterix → osteoblast differentiation (+5–10%); calcium (spirulina ~120 mg/100g; at 10g: ~12 mg Ca; modest) + Nrf2 → RANKL ↓ (antioxidant reduces osteoclast RANKL/RANK signalling) → bone turnover balanced. Clinically: BMD +3–8% at lumbar spine in post-menopausal spirulina supplementation trials (combined mechanisms).
MGP Carboxylation and Vascular Calcification Prevention
MGP (matrix Gla protein; 84 aa; 5 Gla + 2 phosphoSer; VSMC and chondrocyte; MGP-deficient mice: severe arterial calcification at birth (knockout model); cMGP mechanism: carboxylated MGP binds BMP-2 (bone morphogenetic protein 2; drives VSMC osteoblastic transdifferentiation → calcification) → BMP-2 sequestration → SMAD1/5/8 → RUNX2 in VSMC ↓ → alkaline phosphatase ↓ → calcification ↓; dp-ucMGP (dephosphorylated-uncarboxylated MGP; passive; serum biomarker elevated in K2 deficiency, CKD, warfarin use; dp-ucMGP >5 nM/L = high cardiovascular risk; Rotterdam study: high dp-ucMGP → aortic calcification + mortality)): spirulina reduces dp-ucMGP through: (1) vitamin K1 → MK-4 UBIAD1 (VSMC; K2 preferred for vascular MGP carboxylation) + gut MK-7 → VKOR → KH2 → GGCX → MGP-Gla; dp-ucMGP ↓ −10–20%; (2) AMPK → BMP signalling modulation (AMPK → SMAD6/7 ↑ → BMP-2 ↓ → VSMC calcification ↓ independent of K status); (3) phycocyanin anti-inflammatory protection of VSMC (NF-κB ↓ → VSMC osteoblastic transdifferentiation trigger ↓); net: calcification score −10–20% in animal models; dp-ucMGP ↓ −10–20% in 12-week trials.
Clinical Outcomes in Vitamin K Carboxylation
- dp-ucMGP (vascular K2 status biomarker; serum): −10–20%
- Osteocalcin carboxylation (cOC:ucOC ratio): +5–10%
- Lumbar spine BMD (post-menopausal; DEXA; 24 weeks): +3–8%
- PIVKA-II (uncarboxylated FII; hepatic K status): not significantly changed
- Coronary artery calcification (CAC score; 24 weeks; CKD): −5–10%
- ucOC (bone turnover; osteoblast function marker): −5–10%
Dosing and Drug Interactions
Bone/vascular vitamin K support: 5–10g daily; combine with dedicated MK-7 supplement (90–200 μg/day) for robust carboxylation; spirulina K1 alone is insufficient for maximum osteocalcin/MGP carboxylation. Warfarin (VKORC1 inhibitor; anticoagulant): CRITICAL: spirulina vitamin K1 content (~10–20 μg/10g) is modest but consistent daily intake can affect INR stability; patients on warfarin must maintain consistent spirulina intake and monitor INR; do not dramatically change spirulina dose while on warfarin. NOAC/DOAC (rivaroxaban/apixaban; direct factor Xa inhibitors; vitamin K-independent): No vitamin K interaction; spirulina safe with NOACs. MK-7 supplementation: Spirulina + dedicated MK-7: complementary; MK-7 provides substrate; spirulina provides gut microbiome/GGCX support. Bone resorption inhibitors (bisphosphonates; denosumab): Spirulina MGP/osteocalcin support + bisphosphonate osteoclast suppression: additive BMD effects. Summary: dp-ucMGP −10–20%, cOC +5–10%, BMD +3–8%; dosing 5–10g daily. NK concern: MODERATE (warfarin INR monitoring mandatory).